Pancreatic Cancer Research

ResearcherYonsei UniversityActive in the last 2 years

Jung Hyun Jo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2641-8873; OpenAlex author ID A5084067051. Sources: OpenAlex.

Their work

Papers
32 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
51
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 4 papers · 2022: 5 papers · 2023: 3 papers · 2024: 6 papers · 2025: 3 papers · 2026: 2 papers

Papers 32

  1. FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study. Last author DOI 10.1016/j.tranon.2026.103085↗
  2. Disulfiram/Copper Complex Induces Cytotoxicity in Pancreatic Cancer Cells and 5-Fluorouracil-Resistant Cells through Nuclear Factor E2-Related Factor-2 Suppres… Co-author DOI 10.5009/gnl250028↗
  3. Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Co-author DOI 10.1016/j.pan.2025.02.007↗
  4. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Co-author DOI 10.1186/s12885-025-15285-4↗
  5. A New Staining Method Using Methionyl-tRNA Synthetase 1 Antibody for Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology of Pancreatic Cancer. Co-author DOI 10.3390/diagnostics15141783↗
  6. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  7. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
  8. Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Co-author DOI 10.1038/s41416-023-02520-7↗
  9. Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1038/s41598-024-52909-4↗
  10. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. Co-author DOI 10.1177/17588359241279688↗
  11. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with … Co-author DOI 10.1186/s13073-024-01287-7↗
  12. Copula graphic estimation of the survival function with dependent censoring and its application to analysis of pancreatic cancer clinical trial. Co-author DOI 10.1177/09622802231158812↗
  13. Difference of Risk of Pancreatic Cancer in New-Onset Diabetes and Long-standing Diabetes: A Population-based Cohort Study. Co-author DOI 10.1210/clinem/dgac728↗
  14. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective stud… Co-author DOI 10.3389/fonc.2023.1206565↗
  15. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34144↗
  16. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. First author DOI 10.3390/cancers14010236↗
  17. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Co-author DOI 10.3390/cancers14051244↗
  18. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Co-author DOI 10.3390/cancers14194672↗
  19. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  20. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  21. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jgh.15265↗
  22. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08898-y↗
  23. Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. Co-author DOI 10.2196/21088↗
  24. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-020-04051-x↗
  25. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Co-author DOI 10.1016/j.pan.2020.05.017↗
  26. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  27. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Co-author DOI 10.4251/wjgo.v12.i2.182↗
  28. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000001319↗
  29. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. First author DOI 10.4251/wjgo.v10.i11.421↗
  30. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  31. Clinical characteristics of second primary pancreatic cancer. Co-author DOI 10.1371/journal.pone.0179784↗
  32. Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Co-author DOI 10.1097/mpa.0000000000000163↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Moon Jae Chung · 26 shared papers, 2014–2026 · strength 3.51
  2. Hee Seung Lee · 25 shared papers, 2017–2025 · strength 3.47
  3. Seungmin Bang · 25 shared papers, 2014–2025 · strength 3.39
  4. Jeong Youp Park · 25 shared papers, 2014–2026 · strength 3.38
  5. Si Young Song · 24 shared papers, 2014–2024 · strength 3.03
  6. Seung Woo Park · 23 shared papers, 2014–2024 · strength 2.91
  7. Mi‐Suk Park · 9 shared papers, 2017–2025 · strength 1.34
  8. Huapyong Kang · 10 shared papers, 2017–2024 · strength 1.12
  9. Jae Hee Cho · 5 shared papers, 2022–2026 · strength 1.09
  10. Sung Ill Jang · 5 shared papers, 2022–2026 · strength 1.09
  11. Jiyoung Keum · 7 shared papers, 2020–2025 · strength 1.07
  12. Seung‐seob Kim · 5 shared papers, 2020–2025 · strength 0.85
  13. Ho Kyoung Hwang · 5 shared papers, 2020–2024 · strength 0.68
  14. Jee Hoon Kim · 3 shared papers, 2024–2026 · strength 0.65
  15. Kyung In Shin · 3 shared papers, 2024–2025 · strength 0.56
  16. Hyungsik Roger Moon · 3 shared papers, 2023–2024 · strength 0.55
  17. Chang Moo Kang · 4 shared papers, 2020–2024 · strength 0.51
  18. Jae Bock Chung · 4 shared papers, 2014–2025 · strength 0.46
  19. Dawoon Jung · 3 shared papers, 2021–2023 · strength 0.44
  20. Chan Su Park · 2 shared papers, 2023–2024 · strength 0.34
  21. In Rae Cho · 4 shared papers, 2017–2021 · strength 0.34
  22. Eun Kyoung Kim · 1 shared paper, 2026 · strength 0.33
  23. Chang‐Hwan Park · 2 shared papers, 2024 · strength 0.33
  24. Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
  25. Eui Joo Kim · 2 shared papers, 2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.